Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
Goyal, Gaurav , Lau, Denise , Nagle, Alison M., Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Tobin, W. Oliver , Liu, Minetta C. , Tobin, W Oliver , Goyal, Guarav , Vassallo, Robert , Ryu, Jay H , Rech, Karen L. , Koster, Matthew J. , Bennani, N. Nora , Shah, Meera , Go, Ronald S.

Mayo Clinic

Blood | January 29, 2019 | Volume: 133 | Issue: 14 | Pages: 1607-1610

10.1182/blood-2018-12-893917 | PMID 30696619 Get It

Skull Base Manifestations of Erdheim-Chester Disease: A Case Series and Systematic Review
Marinelli, John P. , Peters, Pierce A., Lane, John I. , Carlson, Matthew L. , Vaglio, Augusto , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | January 28, 2019 | Volume: 85 | Issue: 4 | Pages: E693-E701

10.1093/neuros/nyz027 | PMID 30828728 Get It

Abstract BACKGROUND Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis. Up to 50% of patients develop central nervous system involvement, and a subset of these patients can present with isolated tumor-like masses. OBJECTIVE To describe the skull base manifestations of ECD with an emphasis on aspects most pertinent to surgeons who may be referred such patients for primary evaluation. METHODS Scopus, Web of Science, and PubMed were searched from database inception to May 1, 2018 for articles reporting skull base ECD. An institutional retrospective analysis of all patients treated at the authors’ institution since January 1, 1996 was also performed to supplement these data. RESULTS Of 465 retrieved articles, 18 studies totaling 20 patients met inclusion criteria. Institutional review identified an additional 7 patients. Collectively, the median age at diagnosis was 49 yr (interquartile range, 42-58) with a 4:1 male-to-female ratio. Patients frequently presented with diplopia (48%), headache (30%), dysarthria (22%), and vertigo or imbalance (22%), though trigeminal hypesthesia (11%), facial nerve paresis (7%), hearing loss (7%), and trigeminal neuralgia (7%) were also observed. ECD commonly mimicked meningioma (33%), trigeminal schwannoma (8%), neurosarcoidosis (8%), and skull base lymphoma (8%). CONCLUSION Discrete skull base lesions frequently mimic more common pathology such as meningioma or cranial nerve schwannomas. Medical therapy comprises the initial treatment for symptomatic skull base disease. Surgical resection is not curative and the utility of surgical intervention is largely limited to biopsy to establish diagnosis and/or surgical debulking to relieve mass effect.
Prevalence of Sporadic Vestibular Schwannoma: Reconciling Temporal Bone, Radiologic, and Population-based Studies
Marinelli, John P. , Lohse, Christine M. , Carlson, Matthew L. , Grossardt, Brandon R.

Mayo Clinic

Otology & Neurotology | January 26, 2019 | Volume: 40 | Issue: 3 | Pages: 384-390

10.1097/mao.0000000000002110 | PMID 30688755 Get It

Objective: Reported epidemiologic data surrounding vestibular schwannoma (VS) are controversial. Temporal bone prevalence studies have suggested that VS affects up to 2.4% of the population, whereas magnetic resonance imaging (MRI) studies have reported VS to affect 0.017%. Moreover, existing population-based data seem to underestimate the commonness of VS. In an attempt to reconcile temporal bone, radiologic, and population-based reports regarding VS, the current study was conceived to determine the modern prevalence of VS using a unique epidemiological database. Patients: All persons living in Olmsted County, Minnesota on January 1, 2017 with a confirmed diagnosis of sporadic VS identified using the Rochester Epidemiology Project (REP) medical records-linkage system. Main Outcome Measures: Prevalence of all VS and asymptomatic, incidentally diagnosed VS. Results: Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons. The prevalence increased with older age, reaching 212.4 per 100,000 in those ≥ 70 years. Including only persons who have undergone head MRI, the prevalence of asymptomatic, incidentally diagnosed VS was 69.9 per 100,000 among adults age 20 years and older. Conclusions: Using the unique infrastructure of the REP, the current study suggests that the clinical prevalence of sporadic VS approximates 1 in 2,000 adults and 1 in every 500 persons aged 70 years and older, with the prevalence of incidentally diagnosed tumors closely paralleling past MRI studies. These data characterize a shift in the modern patient demographic of sporadic VS, as now many people bearing a diagnosis of VS would have previously died without knowledge of their disease. Moreover, they typify an unfolding transition from an era of microsurgery and radiosurgery to the beginnings of an era that will be largely comprised of “chronic disease management.”
P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
Dulai, Parambir S. , Amiot, Aurélien , Singh, Siddharth , Serrero, Mélanie , Jairath, Vipul , Filippi, Jérôme, Kane, Sunanda V. , Bouhnik, Yoram , Sandborn, William J. , Lasch, Karen, Rosario, Maria , Feagan, Brian G. , Bojic, Daniela, Trang-Poisson, Caroline, Shen, Bo , Altwegg, Romain , Sands, B E, Colombel, J F, Carbonnel, Franck , Bohm, Matthew , Bourrier, Anne, Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Peyrin‐Biroulet, Laurent , Pariente, Benjamin , Loftus, Edward V. , Roblin, Xavier , Buisson, Anthony , Siegel, Corey A , Trang, Caroline , Hudesman, David , Lukin, Dana J.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S316-S316

10.1093/ecco-jcc/jjy222.537 Get It

Access to Urological Care and Internet Connectivity in the United States: A Geospatial Analysis
Nichols, Paige , Kohn, Taylor P. , Boorjian, Stephen A. , Gettman, Matthew T., Patel, Hiten D. , Stimson, C.J., Johnson, Michael H. , Nichols, Paige E, Haney, Nora M. , Pierorazio, Phillip

Mayo Clinic

Urology Practice | January 25, 2019 | Volume: 6 | Issue: 5 | Pages: 275-281

10.1097/upj.0000000000000018 | PMID 37317359 Get It

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Hálfdánarson, Þorvarður R. , Foster, Nathan R. , Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C. , McCullough, Ann E. , Ames, Matthew M. , Jaffe, Jeffrry P., Halfdanarson, Thorvardur R , Alberts, Steven R.

Mayo Clinic

The Oncologist | January 24, 2019 | Volume: 24 | Issue: 5 | Pages: 589-e160

10.1634/theoncologist.2018-0878 | PMID 30679315 Get It

Abstract Lessons Learned Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy. The dual EGFR-directed therapy resulted in increased toxicity. Background Gemcitabine is active in patients with advanced pancreatic adenocarcinoma. The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. Methods Eligible patients with metastatic adenocarcinoma of the pancreas were randomized to either gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A) or the same combination with the addition of panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B). The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, the confirmed response rate, and toxicity. Comparison between arms for the primary endpoint was done with a one-sided log-rank test, and a p value less than .20 was considered statistically significant. Response rate comparison was done with Fisher's exact test. All other reported p values are two-sided. Results A total of 92 patients were randomized, 46 to each arm. The median overall survival was 4.2 months in Arm A and 8.3 months in Arm B (hazard ratio, 0.817; 95% confidence interval [CI], 0.530–1.260; p = .1792). The progression-free survival was 2.0 months in Arm A and 3.6 months in Arm B (hazard ratio, 0.843; 95% CI, 0.555–1.280; p = .4190). A partial confirmed response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (p = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients on Arm B compared with those on Arm A (82.6% vs. 52.2%; p = .0018). Conclusion Dual EGFR-directed therapy resulted in a significant prolongation of overall survival in patients with advanced adenocarcinoma of the pancreas but was associated with substantially increased toxicities. Dual EGFR-directed therapy in combination with gemcitabine alone cannot be recommended for further study, as single-agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.
Frequency‐dependent lipid raft uptake at rat diaphragm muscle axon terminals
Porras, Maria A. Gonzalez , Fogarty, Matthew J. , Gransee, Heather M. , Gonzalez Porras, Maria A, Gransee, Heather M , Sieck, Gary C. , Mantilla, Carlos B. , Fogarty, Matthew J

Mayo Clinic

Muscle & Nerve | January 24, 2019 | Volume: 59 | Issue: 5 | Pages: 611-618

10.1002/mus.26421 | PMID 30677149 Get It

ABSTRACT Introduction : In motor neurons, cholera toxin B (CTB) binds to the cell‐surface ganglioside GM1 and is internalized and transported via structurally unique components of plasma membranes (lipid rafts). Methods : Lipid raft uptake by axon terminals adjoining type‐identified rat diaphragm muscle fibers was investigated using CTB and confocal imaging. Results : Lipid raft uptake increased significantly at higher frequency stimulation (80 Hz), compared with lower frequency (20 Hz) and unstimulated (0 Hz) conditions. The fraction of axon terminal occupied by CTB was ∼45% at 0‐ or 20‐Hz stimulation, and increased to ∼65% at 80 Hz. Total CTB fluorescence intensity also increased (∼20%) after 80‐Hz stimulation compared with 0 Hz. Discussion : Evidence of increased lipid raft uptake at high stimulation frequencies supports an important role for lipid raft signaling at rat diaphragm muscle axon terminals, primarily for motor units physiologically activated at the higher frequencies. Muscle Nerve 59:611–611, 2019
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Lundt, Emily S. , Therneau, Terry M. , Vemuri, Prashanthi , Lowe, Val J. , Kantarci, Kejal , Gunter, Jeffrey L. , Senjem, Matthew L. , Graff-Radford, Jon, Albertson, Sabrina M., Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Boeve, Bradley F. , Jones, David T. , Graff-Radford, Jon, Schwarz, Christopher G. , Lundt, Emily S

Mayo Clinic

Brain | January 20, 2019 | Volume: 142 | Issue: 4 | Pages: 1148-1160

10.1093/brain/awz025 | PMID 30759182 Get It

AbstractAs more biomarkers for Alzheimer’s disease and age-related brain conditions become available, more sophisticated analytic approaches are needed to take full advantage of the information they convey. Most work has been done using categorical approaches but the joint relationships of tau PET, amyloid PET and cortical thickness in their continuous distributions to cognition have been under-explored. We evaluated non-demented subjects over age 50 years in the Mayo Clinic Study of Aging, 2037 of whom had undergone 3 T MRI scan, 985 amyloid PET scan with 11C-Pittsburgh compound B (PIB) and MRI, and 577 PIB-PET, 18F-AV1451 flortaucipir PET and MRI. Participants received a nine-test cognitive battery. Three test scores (logical memory delayed recall, visual reproduction delayed recall and auditory verbal learning test delayed recall) were used to generate a memory composite z-score. We used Gradient Boosting Machine models to analyse the relationship between regional cortical thickness, flortaucipir PET signal, PIB-PET signal and memory z-scores. Age, education, sex and number of test exposures were included in the model as covariates. In this population-based study of non-demented subjects, most of the associations between biomarkers and memory z-scores accrued after 70 years of age. Entorhinal cortex exhibited the strongest associations between biomarkers and memory z-scores. Other temporal regions showed similar but attenuated associations, and non-temporal regions had negligible associations between memory z-scores and biomarkers. Entorhinal flortaucipir PET signal, PIB-PET signal and entorhinal cortical thickness were independently and additively associated with declining memory z-scores. In contrast to global PIB-PET signal where only very high amyloid-β levels were associated low memory z-scores, entorhinal flortaucipir PET signal just above background levels was associated with low memory z-scores. The lowest memory z-scores occurred with the confluence of elevated entorhinal flortaucipir PET signal and lower entorhinal cortical thickness.